* severe or critically patients with covid-19 * have received neutralizing antibodies or convalescent plasma therapy due to covid-19 * child-pugh grade c or acute liver failure * chronic renal failure (egfr\<30 ml/min) * grade iii or iv cardiac function, or known left ventricular ejection fraction \< 30% * known or suspected history of active or extrapulmonary tuberculosis * patients who are allergic to the active ingredient of the drug * pregnant and lactating women

* severe or critically patients with covid-19 * have received neutralizing antibodies or convalescent plasma therapy due to covid-19 * child-pugh grade c or acute liver failure * chronic renal failure (egfr\<30 ml/min) * grade iii or iv cardiac function, or known left ventricular ejection fraction \< 30% * known or suspected history of active or extrapulmonary tuberculosis * patients who are allergic to the active ingredient of the drug * pregnant and lactating women

severe or critically patients with covid-19 have received neutralizing antibodies or convalescent plasma therapy due to covid-19 child-pugh grade c or acute liver failure chronic renal failure (egfr<30 ml/min) grade iii or iv cardiac function, or known left ventricular ejection fraction < 30% known or suspected history of active or extrapulmonary tuberculosis patients who are allergic to the active ingredient of the drug pregnant and lactating women

severe or critically patients with covid-19 have received neutralizing antibodies or convalescent plasma therapy due to covid-19 child-pugh grade c or acute liver failure chronic renal failure (egfr<30 ml/min) grade iii or iv cardiac function, or known left ventricular ejection fraction < 30% known or suspected history of active or extrapulmonary tuberculosis patients who are allergic to the active ingredient of the drug pregnant and lactating women